Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: PTT003
MIFTS: 39

Pituitary-Dependent Cushing's Disease

Categories: Endocrine diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Pituitary-Dependent Cushing's Disease

About this section

MalaCards integrated aliases for Pituitary-Dependent Cushing's Disease:

Name: Pituitary-Dependent Cushing's Disease 12 15 17 70
Pituitary-Dependent Cushing Disease 12 32
Pituitary-Dependent Cushings Disease 54
Pituitary Acth Hypersecretion 44
Overproduction of Acth 12

Classifications:

MalaCards categories:
Anatomical: Endocrine diseases
See all MalaCards categories (disease lists)
ICD10: 32


External Ids:

Disease Ontology 12 DOID:3946
MeSH 44 D047748
NCIt 50 C113210
SNOMED-CT 67 190502001
ICD10 32 E24.0
UMLS 70 C0221406
Sources

Summaries for Pituitary-Dependent Cushing's Disease

About this section
MalaCards based summary : Pituitary-Dependent Cushing's Disease, also known as pituitary-dependent cushing disease, is related to acth-secreting pituitary adenoma and pituitary tumors. An important gene associated with Pituitary-Dependent Cushing's Disease is POMC (Proopiomelanocortin), and among its related pathways/superpathways are Signaling by GPCR and G-Beta Gamma Signaling. The drugs Pasireotide and Metformin have been mentioned in the context of this disorder. Affiliated tissues include pituitary, bone and adrenal gland, and related phenotypes are behavior/neurological and endocrine/exocrine gland

Sources

Related Diseases for Pituitary-Dependent Cushing's Disease

About this section

Diseases related to Pituitary-Dependent Cushing's Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 161)
# Related Disease Score Top Affiliating Genes
1 acth-secreting pituitary adenoma 31.1 USP8 SST PRL POMC NR3C1 CRH
2 pituitary tumors 29.8 SST PRL POMC GH1
3 conn's syndrome 29.6 TRH SST PRL POMC NR3C1 GH1
4 carney complex variant 29.1 USP8 SST PRL POMC GHRH
5 pituitary hormone deficiency, combined, 2 29.0 TRH PRL POMC GHRH GH1
6 pituitary adenoma 28.2 USP8 TRH SST PRL POMC GHRH
7 adenoma 28.0 USP8 TRH SST PRL POMC GHRH
8 pituitary adenoma 4, acth-secreting 11.4
9 acth-dependent cushing syndrome 10.3
10 bronchial adenomas/carcinoids childhood 10.3 SST POMC
11 chiasmal syndrome 10.3 SST POMC
12 functionless pituitary adenoma 10.3 SST POMC
13 colon neuroendocrine neoplasm 10.3 SST POMC
14 binswanger's disease 10.3 SST CRH
15 somatization disorder 10.3 POMC CRH
16 fasting hypoglycemia 10.2 POMC CRH
17 abnormality of glucagon secretion 10.2 SST NR3C1
18 abducens nerve disease 10.2 PRL POMC
19 alzheimer disease 16 10.2 POMC NR3C1
20 adjustment disorder 10.2 POMC CRH
21 benign essential hypertension 10.2 PRL POMC
22 sexual sadism 10.2 PRL CRH
23 inappropriate adh syndrome 10.2 POMC CRH
24 cranial nerve palsy 10.2 PRL POMC
25 dysthymic disorder 10.2 POMC CRH
26 ovarian serous adenofibroma 10.2 POMC NR3C1
27 adrenal cortical hypofunction 10.2 POMC CRH
28 corticosteroid-binding globulin deficiency 10.2 POMC NR3C1
29 withdrawal disorder 10.2 POMC CRH
30 phobic disorder 10.2 POMC CRH
31 steroid inherited metabolic disorder 10.2 PRL POMC
32 thyroid gland medullary carcinoma 10.2 SST POMC
33 olivopontocerebellar atrophy 10.2 SST CRH
34 generalized resistance to thyroid hormone 10.2 TRH PRL
35 non-functioning pituitary adenoma 10.2 SST GH1
36 lymphocytic hypophysitis 10.2 POMC GH1
37 graves disease 1 10.2 TRH POMC
38 opiate dependence 10.2 POMC CRH
39 euthyroid sick syndrome 10.2 TRH POMC
40 fibrous dysplasia/mccune-albright syndrome 10.2 PRL GH1
41 gastrinoma 10.1 SST POMC
42 diencephalic neoplasm 10.1 POMC GH1
43 sebaceous gland disease 10.1 PRL POMC
44 sexual disorder 10.1 PRL POMC
45 hyperaldosteronism, familial, type i 10.1 POMC NR3C1
46 partial third-nerve palsy 10.1 PRL GH1
47 ileus 10.1 SST POMC CRH
48 irritable bowel syndrome 10.1 SST POMC CRH
49 acth-independent macronodular adrenal hyperplasia 10.1 POMC CRH
50 social phobia 10.1 PRL CRH

Graphical network of the top 20 diseases related to Pituitary-Dependent Cushing's Disease:



Diseases related to Pituitary-Dependent Cushing's Disease
Sources

Symptoms & Phenotypes for Pituitary-Dependent Cushing's Disease

About this section

MGI Mouse Phenotypes related to Pituitary-Dependent Cushing's Disease:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 9.97 CRH GHRH NR3C1 POMC PRL SST
2 endocrine/exocrine gland MP:0005379 9.87 CRH GHRH NR3C1 POMC PRL TRH
3 growth/size/body region MP:0005378 9.86 CRH GHRH NR3C1 POMC SST TRH
4 homeostasis/metabolism MP:0005376 9.81 CRH GHRH NR3C1 POMC PRL SST
5 adipose tissue MP:0005375 9.8 CRH GHRH NR3C1 POMC SST
6 liver/biliary system MP:0005370 9.43 CRH GHRH NR3C1 POMC PRL USP8
7 no phenotypic analysis MP:0003012 9.02 CRH NR3C1 POMC SST TRH
Sources

Drugs & Therapeutics for Pituitary-Dependent Cushing's Disease

About this section

Drugs for Pituitary-Dependent Cushing's Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 77)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Pasireotide Approved Phase 4 396091-73-9 9941444
2
Metformin Approved Phase 4 657-24-9 4091 14219
3
Liraglutide Approved Phase 4 204656-20-2 44147092
4
Lactitol Approved, Investigational Phase 4 585-86-4 157355
5
Somatostatin Approved, Investigational Phase 4 38916-34-6, 51110-01-1 53481605
6 Hormone Antagonists Phase 4
7 Hormones Phase 4
8 insulin Phase 4
9 Insulin, Globin Zinc Phase 4
10 Hypoglycemic Agents Phase 4
11
protease inhibitors Phase 4
12 HIV Protease Inhibitors Phase 4
13 Sitagliptin Phosphate Phase 4
14 Dipeptidyl-Peptidase IV Inhibitors Phase 4
15 Incretins Phase 4
16 Orange Approved Phase 3
17
Ketoconazole Approved, Investigational Phase 3 65277-42-1 47576
18 glucocorticoids Phase 2, Phase 3
19 Pharmaceutical Solutions Phase 3
20
Gefitinib Approved, Investigational Phase 2 184475-35-2 123631
21
Bexarotene Approved, Investigational Phase 1, Phase 2 153559-49-0 82146
22
Prednisolone acetate Approved, Vet_approved Phase 2 52-21-1
23
Methylprednisolone Approved, Vet_approved Phase 2 83-43-2 6741
24
Prednisolone Approved, Vet_approved Phase 2 50-24-8 5755
25
Prednisolone phosphate Approved, Vet_approved Phase 2 302-25-0
26
Methylprednisolone hemisuccinate Approved Phase 2 2921-57-5
27
Vorinostat Approved, Investigational Phase 2 149647-78-9 5311
28
Hydrocortisone Approved, Vet_approved Phase 2 50-23-7 5754
29
Hydrocortisone acetate Approved, Vet_approved Phase 2 50-03-3
30
Dopamine Approved Phase 2 62-31-7, 51-61-6 681
31
Cabergoline Approved Phase 2 81409-90-7 54746
32
Rosiglitazone Approved, Investigational Phase 2 122320-73-4 77999
33
Prednisolone hemisuccinate Experimental Phase 2 2920-86-7
34
Maleic acid Experimental Phase 2 110-16-7 444266
35 Gastrointestinal Agents Phase 2
36 Neuroprotective Agents Phase 2
37 Methylprednisolone Acetate Phase 2
38 Protective Agents Phase 2
39 Antiemetics Phase 2
40 Antineoplastic Agents, Hormonal Phase 2
41 Anti-Inflammatory Agents Phase 2
42 Histone Deacetylase Inhibitors Phase 2
43 Protein Kinase Inhibitors Phase 2
44 Hydrocortisone hemisuccinate Phase 2
45 Hydrocortisone 17-butyrate 21-propionate Phase 2
46 Neurotransmitter Agents Phase 2
47 Dopamine Agents Phase 2
48 Dopamine agonists Phase 2
49 Antiparkinson Agents Phase 2
50 Roscovitine Phase 2

Interventional clinical trials:

(show all 45)
# Name Status NCT ID Phase Drugs
1 Adipokine Profile in Patients With Cushing's Disease on Pasireotide Treatment: Correlation With Disease Activity, Insulin Sensitivity and Secretion Parameters Completed NCT03080181 Phase 4 Pasireotide 0.6 MG/ML
2 A Multi-center, Randomized, Open-label, Phase IV Study to Investigate the Management of Pasireotide-induced Hyperglycemia With Incretin Based Therapy or Insulin in Adult Patients With Cushing's Disease or Acromegaly Completed NCT02060383 Phase 4 Pasireotide s.c.;Sitagliptin;Liraglutide;Insulin;Pasireotide LAR;Metformin
3 An Open Label, Multi-center Pasireotide Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Pasireotide Study and Are Judged by the Investigator to Benefit From Continued Pasireotide Treatment Active, not recruiting NCT01794793 Phase 4 Pasireotide;Cabergoline;Pasireotide
4 A Randomized, Double-blind Study to Assess the Safety and Efficacy of Different Dose Levels of Pasireotide (SOM230) Subcutaneous (sc) Over a 6 Month Treatment Period in Patients With de Novo, Persistent or Recurrent Cushing's Disease Completed NCT00434148 Phase 3 Pasireotide
5 A Randomized, Double-blind, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Pasireotide LAR in Patients With Cushing's Disease Completed NCT01374906 Phase 3 pasireotide LAR;SOM230 LAR 30 mg;SOM230 LAR 10 mg
6 An Open-label, Multi-center, Expanded Access Study of Pasireotide s.c. in Patients With Cushing's Disease (Seascape). Completed NCT01582061 Phase 3 Pasireotide sub-cutaneous
7 Prevention of Metabolic Complications of Glucocorticoid Excess - a Randomised, Doubleblind,Placebo Controlled Study Completed NCT01319994 Phase 2, Phase 3 Metformin;Placebo
8 Study of Cabergoline in Treatment of Corticotroph Pituitary Tumor Completed NCT00889525 Phase 3 Cabergoline
9 Phase III, Multi-center, Double-blind, Randomized Withdrawal Study of LCI699 Following a 24 Week, Single-arm, Open-label Dose Titration and Treatment Period to Evaluate the Safety and Efficacy of LCI699 for the Treatment of Patients With Cushing's Disease Completed NCT02180217 Phase 3 osilodrostat;LCI699 matching placebo
10 Compassionate Use Protocol for the Administration of CORLUX® (Mifepristone) in the Treatment of the Signs and Symptoms of Endogenous Cushing's Syndrome Completed NCT01371565 Phase 3 Mifepristone
11 A Phase III, Multi-center, Randomized, Double-blind, 48 Week Study With an Initial 12 Week Placebo-controlled Period to Evaluate the Safety and Efficacy of Osilodrostat in Patients With Cushing's Disease Completed NCT02697734 Phase 3 osilodrostat;osilodrostat Placebo
12 An Open-label Extension Study of Levoketoconazole (2S,4R-ketoconazole) in the Treatment of Endogenous Cushing's Syndrome Active, not recruiting NCT03621280 Phase 3 Levoketoconazole
13 An Open-label Study of the Safety, Pharmacokinetics and Pharmacodynamics of Mifepristone in Children With Refractory Cushing's Disease Withdrawn NCT01925092 Phase 3 mifepristone
14 Targeted Therapy With Gefitinib in Patients With USP8-mutated Cushing's Disease Unknown status NCT02484755 Phase 2 Gefitinib
15 Preoperative Bexarotene Treatment for Cushing's Disease Unknown status NCT00845351 Phase 1, Phase 2 Bexarotene
16 Extension Study to Assess the Safety and Efficacy of Pasireotide in Patients With Cushing's Disease Completed NCT00171951 Phase 2 Pasireotide
17 A Multicenter, Open Label Study to Assess the Safety and Efficacy of 600 µg SOM230, Administered Subcutaneously, b.i.d. in Patients With Cushing's Disease Completed NCT00088608 Phase 2 SOM230 s.c.
18 A Proof of Concept, Open-label, Forced Titration, Multi-center Study to Assess the Safety/Tolerability and Efficacy of 10-weeks Treatment of LCI699 in Patients With Cushing's Disease Completed NCT01331239 Phase 2 LCI699
19 Targeting Iatrogenic Cushing's Syndrome With 11β-hydroxysteroid Dehydrogenase Type 1 Inhibition (TICSI) Recruiting NCT03111810 Phase 2 AZD4017 and prednisolone;Placebo Oral Tablet and prednisolone
20 A Phase 2 Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease Recruiting NCT03774446 Phase 2 Seliciclib
21 A Phase II, Multicenter, Open-label, Non-comparative Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Tolerability of Osilodrostat in Children and Adolescent Patients With Cushing's Disease Recruiting NCT03708900 Phase 2 LCI699
22 The Effect of Vorinostat on ACTH Producing Pituitary Adenomas in Cushing s Disease Recruiting NCT04339751 Phase 2 Vorinostat
23 An Open Label, Multicenter Study Evaluating the Safety and Efficacy of Short Term (6 Weeks) Rosiglitazone Treatment in Patient's With Cushing's Disease Terminated NCT00612066 Phase 2 rosiglitazone maleate
24 Treatment of Pituitary Cushing Disease With a Selective CDK Inhibitor, R-roscovitine Terminated NCT02160730 Phase 2 R-roscovitine
25 A Phase II Trial to Assess the Efficacy and Safety of Pasireotide s.c. Alone or in Combination With Cabergoline in Patients With Cushing's Disease Terminated NCT01915303 Phase 2 Pasireotide with or without cabergoline
26 Cognitive Sequels of Cushing Syndrome Unknown status NCT02603653
27 Etat de santé Des Patients Suivis Pour Une Maladie de Cushing Dans la région Grand-Ouest de 1990 à 2015 Unknown status NCT03297892
28 Cognition, Steroids, and Imaging in Cushings Disease Completed NCT00081341
29 The Factors Associated With the Recurrence in Patients With Cushing Disease Completed NCT02233335
30 Rhinological Outcomes in Endonasal Pituitary Surgery: A Multi-Center Observational Cohort Study Completed NCT01504399
31 National Swedish Study in Cushing´s Disease Incidence and Outcomes Completed NCT02350153
32 Impact of [11C]-Methionine PET/MRI in the Detection of Pituitary Adenomas Secreting ACTH and Causing Cushing's Disease Completed NCT03346954
33 Evolution of the Metabolic, Cardiovascular, Bone Complications and of the Quality of Life in Cushing's Disease Completed NCT02568982
34 Treatment Outcomes for Patients With Cushing's Syndrome: a Prospective Data Collection Study Recruiting NCT03364803
35 Non-interventional Study for the Generation of Long Term Safety and Efficacy Data of Pasireotide s.c. in Patients With Cushing's Disease (Post-Authorization Safety Study) Recruiting NCT02310269 SOM230
36 Long-Term Follow UP of Survivors of Pediatric Cushing Disease Recruiting NCT03831958
37 A Clinical and Genetic Investigation of Pituitary and HYPOTHALAMIC Tumors and Related Disorders Recruiting NCT00001595
38 Discriminant Capacity and Thresholds of Salivary Cortisol in Chemiluminescence in the Diagnosis of Hypercorticisms: Phase III Diagnostic Evaluation Study Recruiting NCT03974789
39 Clinical Study on Circadian Genes Dysregulation in Patients With Glucocorticoid Disorders Recruiting NCT04374721
40 Prospective Observational Study of Diagnostic Yield in Cushing's Disease Using Deep Learning Based Denoising MRI Recruiting NCT04121988
41 Usefulness of Hair Cortisol/Cortisone Concentrations for the Monitoring of Medical Treatment in Patients With Cushing's Disease Recruiting NCT04201444
42 Seoul National University Pituitary Disease Cohort Study Recruiting NCT03474601
43 Corticotrophin-Releasing Hormone (CRH) Stimulation for 18F-FDG-PET Detection of Pituitary Adenoma in Cushing's Disease Not yet recruiting NCT04569591 Acthrel
44 A Prospective, Multicenter, Randomized Controlled Study of Postoperative Thrombosis Prevention in Patients With Cushing's Disease Not yet recruiting NCT04486859 LMWH/Rivaroxaban
45 Role of Adipokines in Long-term Cardiovascular Risk in Cured Cushing's Patients Terminated NCT00881283

Search NIH Clinical Center for Pituitary-Dependent Cushing's Disease

Cochrane evidence based reviews: pituitary acth hypersecretion

Sources

Genetic Tests for Pituitary-Dependent Cushing's Disease

About this section
Sources

Anatomical Context for Pituitary-Dependent Cushing's Disease

About this section

MalaCards organs/tissues related to Pituitary-Dependent Cushing's Disease:

40
Pituitary, Bone, Adrenal Gland, Hypothalamus
Sources

Publications for Pituitary-Dependent Cushing's Disease

About this section

Articles related to Pituitary-Dependent Cushing's Disease:

(show top 50) (show all 111)
# Title Authors PMID Year
1
[Evaluation of the accuracy of inferior petrosal sinus sampling in the differential diagnosis of ACTH-dependent Cushing's syndrome]. 61 54
17468067 2007
2
The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5. 54 61
15817922 2005
3
Apparently complete restoration of normal daily adrenocorticotropin, cortisol, growth hormone, and prolactin secretory dynamics in adults with Cushing's disease after clinically successful transsphenoidal adenomectomy. 54 61
11095430 2000
4
Growth hormone and prolactin are secreted more irregularly in patients with Cushing's disease. 54 61
10792343 2000
5
A comparison of the effects of human and ovine corticotropin-releasing hormone on the pituitary-adrenal axis. 61 54
7852498 1995
6
Differential release of proopiomelanocortin-derived peptides from the human pituitary: evidence from a panel of two-site immunoradiometric assays. 61 54
8157708 1994
7
Cushing's disease and hyperprolactinemia due to a mixed ACTH- and prolactin-secreting pituitary macroadenoma. 61 54
1656408 1991
8
Quality of Life in Cushing's disease: A long term issue? 61
29625700 2018
9
PRKAR1A mutation causing pituitary-dependent Cushing disease in a patient with Carney complex. 61
28522647 2017
10
Ambulatory Arterial Stiffness Indexes in Cushing's Syndrome. 61
28226362 2017
11
Coronary microvascular function in patients with Cushing's syndrome. 61
22851333 2013
12
Pituicytoma in a patient with Cushing's disease: case report and review of the literature. 61
20945102 2012
13
Prolactin measurement during inferior petrosal sinus sampling improves the localization of pituitary adenomas in Cushing's disease. 61
22243215 2012
14
Psychosomatic aspects of Cushing's syndrome. 61
19960264 2010
15
Mortality in Cushing's disease. 61
20829622 2010
16
Treatment of pituitary-dependent Cushing's disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trial. 61
18957506 2009
17
Cushing's disease and pregnancy: case report and literature review. 61
17599863 2007
18
Combined therapy of somatostatin analogues and dopamine agonists in the treatment of pituitary tumours. 61
17413190 2007
19
[The desmopressin test in the diagnosis of Cushing's disease]. 61
17642202 2007
20
Personality characteristics and quality of life in patients treated for Cushing's syndrome. 61
16487442 2006
21
Pharmacologic management of Cushing syndrome : new targets for therapy. 61
15783246 2005
22
Profound amplification of secretory-burst mass and anomalous regularity of ACTH secretory process in patients with Nelson's syndrome compared with Cushing's disease. 61
15163342 2004
23
Baseline characteristics and the effects of two years of growth hormone replacement therapy in adults with growth hormone deficiency previously treated for Cushing's disease. 61
15104557 2004
24
The role of somatostatin analogs in Cushing's disease. 61
16132202 2004
25
Somatostatin receptors in pituitary function, diagnosis and therapy. 61
15281350 2004
26
Circadian variation in Cushing's disease and pseudo-Cushing states by analysis of F and ACTH pulsatility. 61
12398238 2002
27
An exception to the rule: ectopic ACTH production from functional neuroendocrine tissue in an ovarian dermoid cyst. 61
11765050 2001
28
Cushing's disease due to plurihormonal adrenocorticotropic hormone and gonadotropin-producing pituitary adenoma. 61
11603817 2001
29
Medical treatment of canine pituitary-dependent hyperadrenocorticism (Cushing's disease). 61
11570123 2001
30
Effect of the serotonin antagonists ritanserin and ketanserin in Cushing's disease. 61
11141696 2000
31
Ectopic corticotroph adenoma in the cavernous sinus: case report. 61
10515490 1999
32
Cushing's syndrome in pregnancy treated by ketoconazole: case report and review of the literature. 61
10451809 1999
33
Pituitary hyperplasia. 61
11081195 1999
34
Medical therapy for Cushing's disease. 61
10207692 1999
35
Undetectable urinary free cortisol concentrations in a case of Cushing's disease. 61
10069659 1999
36
Clinical correlates of major depression in Cushing's disease. 61
9780396 1998
37
The modulation of glucocorticoid receptor content by 3-O-methyl-D-glucose transport in human mononuclear leukocyte in obesity. 54
9854680 1998
38
Growth hormone and prolactin responses to corticotrophin-releasing-hormone in patients with Cushing's disease: a paracrine action of the adenomatous corticotrophic cells? 61
9876339 1998
39
Corticotropin-dependent Cushing's syndrome in older people: presentation of five cases and therapeutical use of ketoconazole. 61
9670876 1998
40
Ectopic ACTH production by a bronchial carcinoid tumour responsive to desmopressin in vivo and in vitro. 61
9425403 1997
41
Greater disorderliness of ACTH and cortisol release accompanies pituitary-dependent Cushing's disease. 61
9150699 1997
42
Risk factors and long-term outcome in pituitary-dependent Cushing's disease. 61
8675592 1996
43
Human kidney 11 beta-hydroxysteroid dehydrogenase: regulation by adrenocorticotropin? 54
8616526 1996
44
Pre- and postoperative investigations of hepatic glucose production and leucine turnover in Cushing's disease utilizing stable isotope techniques. 61
8557243 1995
45
Extrasellar, intracavernous sinus adrenocorticotropin-releasing adenoma causing Cushing's disease. 61
7775621 1995
46
Ectopic ACTH syndrome. 61
7626446 1995
47
Differential diagnosis in cushing syndrome. Use of corticotropin-releasing hormone. 54
7891545 1995
48
Gamma knife surgery for Cushing's disease. 61
7892664 1995
49
[Surgical interventions of the adrenal gland. Diagnosis and results of treatment]. 61
7817448 1994
50
Role of bilateral adrenalectomy in Cushing's disease. 61
7725729 1994
Sources

Variations for Pituitary-Dependent Cushing's Disease

About this section
Sources

Expression for Pituitary-Dependent Cushing's Disease

About this section
Search GEO for disease gene expression data for Pituitary-Dependent Cushing's Disease.
Sources

Pathways for Pituitary-Dependent Cushing's Disease

About this section

Pathways related to Pituitary-Dependent Cushing's Disease according to GeneCards Suite gene sharing:

(show all 11)
# Super pathways Score Top Affiliating Genes
1
Signaling by GPCR 65
Show member pathways
 13.7 USP8 TRHR TRH SST POMC NR3C1
2
G-Beta Gamma Signaling 63
Show member pathways
 12.65 POMC GHRH GH1 CRH
3
Peptide ligand-binding receptors 65
Show member pathways
 12.56 TRHR TRH SST PRL POMC NR3C1
4
Relaxin signaling pathway 36
Show member pathways
 12.15 SST POMC GHRH GH1
5
Prolactin Signaling Pathway 1 36
Show member pathways
 12.12 PRL NR3C1 GH1
6
G alpha (s) signalling events 65
11.66 POMC GHRH CRH
7
Glucocorticoid receptor regulatory network 1
11.25 PRL POMC NR3C1
8
Growth hormone receptor signaling 65
Show member pathways
 11.07 PRL GH1
9
Development_Leptin signaling via JAK/STAT and MAPK cascades 23
Show member pathways
 10.91 TRH POMC
10
Antipsychotics Pathway (Metabolic Side Effects), Pharmacodynamics 60
10.67 PRL POMC
11
Glucocorticoid Pathway (HPA Axis), Pharmacodynamics 60
9.8 POMC CRH
Sources

GO Terms for Pituitary-Dependent Cushing's Disease

About this section

Cellular components related to Pituitary-Dependent Cushing's Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.63 SST PRL POMC GHRH GH1 CRH
2 extracellular region GO:0005576 9.17 TRH SST PRL POMC GHRH GH1
3 endosome lumen GO:0031904 8.96 PRL GH1

Biological processes related to Pituitary-Dependent Cushing's Disease according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 9.87 TRHR TRH PRL POMC NR3C1 GH1
2 G protein-coupled receptor signaling pathway GO:0007186 9.73 TRHR TRH SST POMC GHRH CRH
3 positive regulation of pri-miRNA transcription by RNA polymerase II GO:1902895 9.49 PRL NR3C1
4 positive regulation of JAK-STAT cascade GO:0046427 9.48 PRL GH1
5 positive regulation of multicellular organism growth GO:0040018 9.46 GHRH GH1
6 cell-cell signaling GO:0007267 9.46 TRH SST POMC GHRH
7 response to corticosterone GO:0051412 9.43 TRH CRH
8 JAK-STAT cascade involved in growth hormone signaling pathway GO:0060397 9.4 PRL GH1
9 positive regulation of insulin-like growth factor receptor signaling pathway GO:0043568 9.37 GHRH GH1
10 hormone-mediated apoptotic signaling pathway GO:0008628 8.96 SST CRH
11 cellular response to dexamethasone stimulus GO:0071549 8.8 USP8 NR3C1 CRH

Molecular functions related to Pituitary-Dependent Cushing's Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 9.17 TRH SST PRL POMC GHRH GH1
2 neuropeptide hormone activity GO:0005184 9.16 GHRH CRH
3 prolactin receptor binding GO:0005148 8.96 PRL GH1
Sources

Sources for Pituitary-Dependent Cushing's Disease

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....